IMMUNE NETWORK

  • 제5권1호
  • /
  • Pages.36-44
  • /
  • 2005
  • /
  • 1598-2629(pISSN)
  • /
  • 2092-6685(eISSN)
대한면역학회 (The Korean Association of Immunobiologists)
권호 표지

폐암의 면역세포 치료: 동물 모델에서 수지상 세포를 이용한 Adjuvant Therapy 가능성 연구

Immunocell Therapy for Lung Cancer: Dendritic Cell Based Adjuvant Therapy in Mouse Lung Cancer Model

  • 이석재 (을지대학교 의과대학 흉부외과) ;
  • 김명주 (성균관대학교 의과대학 삼성서울병원 암센터) ;
  • 인소희 (성균관대학교 의과대학 삼성서울병원 암센터) ;
  • 백소영 (성균관대학교 의과대학 삼성서울병원 암센터) ;
  • 이현아 (성균관대학교 의과대학 삼성서울병원 암센터)
  • Lee, Seog-Jae (Department of Thoracic & Cardiovascular Surgery, Eulji University School of Medicine) ;
  • Kim, Myung-Joo (The Cancer Center, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • In, So-Hee (The Cancer Center, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Baek, So-Young (The Cancer Center, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Lee, Hyun-Ah (The Cancer Center, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • 발행 : 2005.03.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: The anti-tumor therapeutic effect of autologous tumor cell lysate pulseddendritic cells (DCs) was studied for non-immunogenic and immune suppressive lung cancer model. To test the possibility as an adjuvant therapy, minimal residual disease model was considered in mouse in vivo experiments. Methods: Syngeneic 3LL lung cancer cells were inoculated intravenously into the C57BL/6 mouse. Autologous tumor cell (3LL) or allogeneic leukemia cell (WEHI-3) lysate pulsed-DCs were injected twice in two weeks. Intraperitoneal DC injection was started one day (MRD model) after tumor cell inoculation. Two weeks after the final DC injection, tumor formation in the lung and the tumor-specific systemic immunity were observed. Tumor-specific lymphocyte proliferation and the IFN-${\gamma}$ secretion were analyzed for the immune monitoring. Therapeutic DCs were cultured from the bone marrow myeloid lineage cells with GM-CSF and IL-4 for 7 days and pulsed with tumor cell lysate for 18 hrs. Results: Compared to the saline treated group, tumor formation was suppressed in 3LL tumor cell lysate pulsed-DC treated group, while 3LL-specific immune stimulation was minimum. WEHI-3-specific immune stimulation occurred in WEHI-3 lysate-pulsed DC treated group, which had no correlation with tumor regression. Conclusion: The data suggest the possible anti-tumor effect of cultured DCs as an adjuvant therapy for minimal residual disease state of lung cancer. The significance of immune modulation in DC therapy including the possible involvement of NK cell as well as antigen-specific cytotoxic T cell activity induction was discussed.

키워드

참고문헌

  1. Steinman RM: The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9;271-296, 1991 https://doi.org/10.1146/annurev.iy.09.040191.001415
  2. Paglia P, Chiodoni C, Rodolfo M, Colombo MP: Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 183;317-322, 1996 https://doi.org/10.1084/jem.183.1.317
  3. Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 392;245-252, 1998 https://doi.org/10.1038/32588
  4. Palucka K, Banchereau J: Dendritic cells: a link between innate and adaptive immunity. J Clin Immunol 19;12-25, 1999 https://doi.org/10.1023/A:1020558317162
  5. Palucka K, Banchereau J: Linking innate and adaptive immunity. Nat Med 5;868-870, 1999 https://doi.org/10.1038/11303
  6. Fernandez N, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, Perricandet M, Tursz T, Maraskovsky E, Zitvogel L: Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo. Nature Medicine 4;405-410, 1999
  7. Azuma T, Horie S, Tomita K, Takahashi T, Tanaka Y, Kashiwase K, Nieda M, Takeuchi T, Ohta N, Shibata Y, Hirai H, Kitamura T: Dendritic cell immunotherapy for patients with metastatic renal cell carcinoma: University of Tokyo experience. Int J Urol 9;340-6, 2002 https://doi.org/10.1046/j.1442-2042.2002.00477.x
  8. Oosterwijk-Wakka J, Tiemessen D, Bleumer I, de Varies I, Jongmans W, Adema G, Debruyne F, de Mulder PH, Oosterwijk E, Mulders PF: Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigen in combination with interleukin-2: A phase I study. J Immunother 25;500-508, 2002 https://doi.org/10.1097/00002371-200211000-00006
  9. Holtl L, Zelle-Rieser C, Gander H, Papesh C, Ramoner R, Bartsch G, Rogatsch H, Barsoum AL, Coggin JH Jr, Thurnher M: Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res 8;3369-3376, 2002
  10. Marten A, Renoth S, Heinicke T, Albers P, Pauli A, Mey U, Caspari R, Flieger D, Hanfland P, Von Ruecker A, EisHubinger A, Muller S, Schwaner I, Lohmann U, Heylmann G, Sauerbruch T, Schtnidt-Wolf I: Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase i/ii trial in patients with metastatic renal cell carcinoma. Hum Gene Ther 14;483-494, 2003 https://doi.org/10.1089/104303403321467243
  11. Gitlitz B, Belldegrun A, Zisman A, Chao D, Pantuck A, Hinkel A, Mulders P, Moldawer N, Tso C, Figlin R: A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma. J Immunother 26;412419, 2003
  12. Nestle F, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 3;328-332, 1998
  13. Banchereau J, Palucka A, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, Coquery S, Wittkowski K, Bhardwaj N, Pineiro L, Steinman R, Fay J: Immune and clinical responses in patients with metastatic melanoma to CD34 (+) progenitor-derived dendritic cell vaccine. Cancer Res 61;6451-6458, 2001
  14. Krause S, Neumann C, Soruri A, Mayer S, Peters J, Andreesen R: The treatment of patients with disseminated malignant melanoma by vaccination with autologous cell hybrids of tumor cells and dendritic cells. J Immunother 25;421-428, 2002 https://doi.org/10.1097/00002371-200209000-00006
  15. Smithers M, O'Connell K, MacFadyen S, Chambers M, Greenwood K, Boyce A, Abdul-Jabbar I, Barker K, Grimmett K, Walpole E, Thomas R: Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen. Cancer Immunol Immunother 52;41-52, 2003
  16. Hersey P, Menzies S, Halliday G, Nguyen T, Farrelly M, DeSilva C, Lett M: Phase I/ll study of treatment with dendritic cell vaccines in patients with dissetninated melanoma. Cancer Immunol Immunother 53;125-134, 2004 https://doi.org/10.1007/s00262-003-0429-0
  17. Haenssle H, Krause S, Emmert S, Zutt M, Kretschmer L, Schtnidberger H, Andreesen R, Soruri A: Hybrid cell vaccination in metastatic melanoma: clinical and immunologic results of phase I/II study. J Immunother 27;147-155, 2004 https://doi.org/10.1097/00002371-200403000-00008
  18. Tjoa B, Erickson S, Bowes V, Ragde H, Kenny G, Cobb O, Ireton R, Troychak M, Boynton A, Murphy G: Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides. Prostate 32;272-278, 1997 https://doi.org/10.1002/(SICI)1097-0045(19970901)32:4<272::AID-PROS7>3.0.CO;2-L
  19. Tjoa B, Simmons S, Bowes V, Ragde H, Rogers M, Elgamal A, Kenny G, Cobb O, Ireton R, Troychak M, Salgaller M, Boynton A, Murphy G: Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 36;39-44, 1998 https://doi.org/10.1002/(SICI)1097-0045(19980615)36:1<39::AID-PROS6>3.0.CO;2-6
  20. Murphy G, Tjoa B, Simmons S, Jarisch J, Bowes V, Ragde H, Rogers M, Elgamal A, Kenny G, Cobb O, Ireton R, Troychak M, Salgaller M, Boynton A: Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific mernbrane antigen pep tides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 38;73-78, 1999 https://doi.org/10.1002/(SICI)1097-0045(19990101)38:1<73::AID-PROS9>3.0.CO;2-V
  21. Barrou B, Benit G, Ouldkaci M, Cussenot O, Salcedo M, Agrawal S, Massicard S, Bercovici N, Ericson M, Thiounn N: Vaccination of prostatectomized prostate cancer patients in biochemical relapse with autologous dendritic cells pulsed with recombinant human PSA. Cancer Immunol Imrnunother 53;453-460, 2004 https://doi.org/10.1007/s00262-003-0451-2
  22. Hirschowitz E, Foody T, Kryscio R, Dickson L, Sturgill J, Yannelli J: Autologous dendritic cell vaccine for non-smallcell lung cancer. J Clin Oncol 22;2808-2815, 2004 https://doi.org/10.1200/JCO.2004.01.074
  23. Hege K, Carbone D: Lung cancer vaccines and gene therapy. Lung Cancer 41;S103-113, 2003 https://doi.org/10.1016/S0169-5002(03)00153-3
  24. Fong L, Hou Y, Rivas A: Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci USA 98;8809-8814, 2001
  25. 서광욱, 이봉호,Choti M: 쥐의 전이성 간암 모델에서 자가 종양 백신을 이용한 면역 치료. J Korean Cancer Assoc 31 ;360-366, 1999
  26. 권희충, 정재민, 김정현, 함용호, 서지숙, 이기호, 김장민, 이한수, 이춘택: Lewis 폐암 마우스 모델 에서 Rerivort Vector나 Adenoviral Vector로 이입된 Herpes Simplex Virus Thymidine Kinase 유전자 치료. 결핵 및 호흡기 질환 49; 298-309, 2000
  27. Park K, Kim G, Jang S, Kim C, Kwon S, Yoo C, Kim Y, Kwon H, Kim C, Han S, Shim Y, Lee C: Genetherapy with GM-CSF, interleukin-4 and herpes simplex virus thymidine kinase shows strong antitumor effect on lung cancer. Anticancer Res 23;1559-1564, 2003
  28. Kojima T, Yamazaki K, Tamura Y, Ogura S, Tani K, Konishi J, Shinagawa N, Kinoshita I, Hizawa N, Yamaguchi E, Dosaka-Akita H, Nishimura M: Granulocyte-macrophage colonystimulating fetor gene-transduced tumor cells combined with tumor-derived gp96 inhibit tumor growth in mice. Hum Gene The 14;715-728, 2003
  29. Salgia R, Lynch T, Skarin A, Lucca J, Lynch C, Jung K, Dranoff G: Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colonystimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol 21;624-630, 2003 https://doi.org/10.1200/JCO.2003.03.091
  30. Sharma S, Yang S, Batra R, Dubinett S: Intratumoral therapy with cytokine gene-modified dendritic cells in murine lung cancer models. Methods Mol Med 75;711-22, 2003
  31. Sharma S, Miller P, Stolina M, Zhu L, Huang M, Paul R, Dubinett S: Multicomponent gene therapy vaccines for lung cancer : effective eradication of established murine tumors in vivo with interleukin-7/herpes simplex thytnidine kinasetransduced autologous tumor and ex vivo activated dendritic cells. Gene Ther 4;1361-1370, 1997 https://doi.org/10.1038/sj.gt.3300531
  32. Hege K, Carbone D: Lung cancer vaccines and gene therapy. Lung Cancer 41;S103-113, 2003 https://doi.org/10.1016/S0169-5002(03)00153-3
  33. Young M, Wright M, Vellody K, Lathers D: Skewed differentiation of bone marrow CD34+ cells of tumor bearers from dendritic toward monocytic cells, and the redirection of differentiation toward dendritic cells by 1 alpha, 25-dihydroxyvitamin D3. Int J Immunopharmaol 21;675-688, 1999 https://doi.org/10.1016/S0192-0561(99)00044-2
  34. Katsenelson NS, Shurin GV, Bykovskaia SN, Shogan J, Shurin MR: Human small cell lung carcinoma and carcinoid tumor regulate dendritic cell maturation and function. Mol Pathol 14; 40-45, 2001 https://doi.org/10.1038/modpathol.3880254
  35. Neuner A, Schindel M, Wildenberg U, Muley T, Lahm H, Fischer J: Cytokine secretion: clinical relevance of immunosuppression in non-small cell lung cancer. Lung Cancer 34; S79-S82, 2001 https://doi.org/10.1016/S0169-5002(01)00350-6
  36. Inoshima N, Nakanishi Y, Minami T, Izutni M, Takayama K, Yoshino I, Hara N: The influence of dendritic cell infiltration and vascular endithelial growth factor expression on the prognosis of non-small-cell lung cancer. Clin Cancer Res 8;3480-3486, 2002
  37. Zeid N, Muller H: S100 positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival. Pathology 25;338-343, 1993 https://doi.org/10.3109/00313029309090853
  38. Zhou Y, McEarchern J, Howard E, Prestano G, Salgaller M, Bosch M: Dendritic cells efficiently acquire and present antigen derived from lung cancer cells and induce antigenspecific T-cell responses. Cancer Immunol Immunother 52, 413-422, 2003 https://doi.org/10.1007/s00262-003-0382-y
  39. Specht J, Wang G, Do M, Lam J, Royal R, Reeves M, Rosenberg S, Hwu P: Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastasis. J Exp Med 186;1213-1221, 1997 https://doi.org/10.1084/jem.186.8.1213
  40. Fields R, Shimizu K, Mule JJ: Murine dendritic cells pulsed with whole tumor Iysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA 95; 9482-9487, 1998
  41. Inaba K, lnaba M, Romani N, Aya H, Dequchi M, Ikehara S, Steinman RM: Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176;1693-1702, 1992 https://doi.org/10.1084/jem.176.6.1693
  42. Dematos P, Abdel-Wahab Z, Vervaert C, Hester D, Seigler H: Pulsing of dendritic cells with cell Iysates from either B 16 melanoma or MCA -106 fibrosarcoma yields equally dffective vaccines against B16 tumors in mice. J Surg Oncol 68;79-91, 1998 https://doi.org/10.1002/(SICI)1096-9098(199806)68:2<79::AID-JSO3>3.0.CO;2-H
  43. Yoon HL, Singh K, Ratner S, Reiners JJ: Phorbol ester effects on splenic lymphocyte composition and cytotoxic T cell activities of SSIN mice: a strain deficient in CD8+ T cells. Carcinogenesis 17;2617-2624, 1996 https://doi.org/10.1093/carcin/17.12.2617
  44. Kemp R, Ronchese F: Tumor-specific Tel, but not Tc2, cells deliver protective antitumor immunity. J Immunol 167; 64976502, 2001
  45. 한국중앙암등록사업 연례 보고서- 보건복지부 한국중앙 암 등록본부, 2002
  46. 이진수: 폐암Overview. 대한의사협회지 1;17-11, 2003
  47. Lee H, In S, Kim M, Baek S, and Lee S: Antitumor immunity modulated by IL-10 producing dendritic cells pulsed with Lewis lung carcinoma cell lysates: Proceedings of 95th Annual meeting of American Association for Cancer Research 45, 2004
  48. Lee H: Dendritic cell based cancer immunotherapy: The 2nd International Symposium on Stem Cells and Cell Therapy May 1, 2004
  49. 이현아, 최광민, 백소영, 이홍기, 정철원: 수지상 세포를 이용한 항암 면역 치료. 생쥐 신장암 모델을 이용한 연구. Immune Network 4;44-52, 2004 https://doi.org/10.4110/in.2004.4.1.44